Samsung Bioepis Launches First Biosimilar Product in Japan with Ustekinumab Therapy
Samsung Bioepis launches its ustekinumab biosimilar in Japan through a partnership with Nipro Corporation, expanding access to affordable treatments for chronic autoimmune diseases.
Jinhan Chung | 21/05/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy